+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Indian genome scientists recommend COVID-19 booster dose for those above 40 years of age

Dec 3, 2021, 12:45 IST
PTI
Booster doseBI
Top Indian genome scientists have recommended a booster dose of COVID-19 vaccines for those above 40 years with preference to high-risk and high-exposure population.
Advertisement

The recommendation was made in the weekly bulletin of the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of COVID-19.

"Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered," the INSACOG bulletin said.

The recommendation came amid demands for a booster dose of covid vaccines by lawmakers during a discussion in the Lok Sabha on the pandemic situation in the country.

Thr INSACOG said genomic surveillance will be critical for early detection of the presence of this variant, to enable necessary public health measures. It also recommended monitoring travel to and from the known affected areas, and contact tracing of COVID-19 cases with an epidemiological link to the affected areas has been implemented along with increased testing.

Advertisement

"Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered, since low levels of neutralising antibodies from current vaccines are unlikely to be sufficient to neutralise Omicron, although risk of severe disease is still likely to be reduced," it said.

SEE ALSO:
Poor demand for Star Health’s IPO forces investment bankers to cut down on promoter offerings; GMP at ₹10 discount
NASA grants $415.6 million to Jeff Bezos’ Blue Origins and more companies to build commercial space stations
Next Article